RE: How many bags will this do today17 Sep 2025 08:58
Hemo science - recent RNS + Ortex quotes - makes great reading 👍🤔👍
When you add these quotes together it makes a superb ingredient mix for Hemo , suffering patients & stockholders
Vlads words RNS -
The Company has already made significant progress in the trial, with early clinical data supporting growing confidence in both safety and potential efficacy.👍👍
Mixed with Vlads words - RNS
:"Partnering with a trusted CDMO like Made Scientific is essential to the success of HG-CT-1, our lead CAR-T therapy. Made's expertise in cell therapy manufacturing will be instrumental in driving the continued progress of this potentially breakthrough therapy for patients with relapsed or refractory AML, fully in line with our identity as a life saving company." 👍👍
Mixed with - RNS
‘demonstrates this confidence and shows that they see considerable upside potential in our share price as we advance HG-CT-1 through clinical development. ." 👍👍
Mixed with - Ortex noted
The biotech sector is known for its cutting-edge research and potential for groundbreaking treatments, positioning companies like Hemogenyx at the forefront of medical
RNS - Pediatrics expansion
This expansion broadens the potential impact and value of HG-CT-1 as we continue to advance toward key inflection points in the clinic. Importantly, it also reinforces the value of Company's robust intellectual property portfolio, which underpins our pipeline and supports long-term strategic growth." 👍👍
Mixed with - RNS
Hemogenyx will present its clinical progress and pipeline as part of the Summit's curated company showcase. Previous Summit participants have successfully secured significant growth capital, underscoring the Summit's reputation as a catalyst for financing and partnerships. 👍👍
Todays RNS - P3 results
Vlads words
These results reinforce the promise of HG-CT-1 as a potential new therapy for one of the most aggressive and intractable forms of leukemia. We remain committed to advancing the clinical development of this therapy to address a critical unmet medical need, while also creating long-term value for our shareholders."
Not forgetting the newal in the crown CBR & CDX
RNS stated
"We are thrilled to announce this critical advancement in our CBR platform, which represents a significant step forward in our mission to develop cutting-edge therapies for unmet medical needs. Overcoming the challenges of efficiently delivering CBRs to myeloid immune cells has been a key focus for our team, and this breakthrough underscores their dedication and ingenuity We remain committed to leveraging this technology to bring transformative therapies to the clinic and, ultimately, to patients in need. Once sufficient resources are available to CBR, we are confident in our ability to translate these scientific breakthroughs into impactful treatments." 👍👍
Mixed together gives highlights the Hemo science map for sure & conten
Sign In
Follow the stocks
